Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis
2018 ◽
Vol 59
(9)
◽
pp. 2121-2127
◽
Keyword(s):
Keyword(s):
2015 ◽
Vol 23
(2)
◽
pp. 619-625
◽
Keyword(s):
2020 ◽
Vol 52
(5)
◽
pp. 1507-1510
2019 ◽
Vol 87
◽
pp. 109-116
◽
Keyword(s):
2017 ◽
Vol 214
(2)
◽
pp. 278-286
◽
Keyword(s):
Keyword(s):